Lynn L. Bergeson focus of Bloomberg BNA Daily Environment Report story “FDA Oversight May Be Required for New, Altered Chemicals, Products, Attorney Says.”

Bloomberg BNA Daily Environment Report reported on Lynn L. Bergeson’s comments regarding final nanotechnology guidances released by the Food and Drug Administration. “The guidances reaffirm the FDA’s position that it has sufficient statutory authorities and policies to oversee the safety of products it regulates, Bergeson said. She expanded on that perspective in a memo her law firm issued. The FDA also restated its view that nanotechnology isn’t inherently safe or harmful, but that specific characteristics of individual products determine safety or harmfulness, she said.”